Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

1.56USD
1:30am IST
Change (% chg)

$0.09 (+6.12%)
Prev Close
$1.47
Open
$1.62
Day's High
$1.63
Day's Low
$1.48
Volume
298,891
Avg. Vol
319,579
52-wk High
$13.27
52-wk Low
$0.74

Latest Key Developments (Source: Significant Developments)

Aclaris Therapeutics' Wart Therapy Meets Main And Secondary Goals In Phase 3 Trial
Tuesday, 17 Sep 2019 

Sept 16 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY EFFICACY ENDPOINTS IN PIVOTAL PHASE 3 TRIAL FOR THE TREATMENT OF COMMON WARTS (THWART-2).ACLARIS THERAPEUTICS INC - HIGHLY STATISTICALLY SIGNIFICANT RESULTS ON ALL SECONDARY EFFICACY ENDPOINTS.ACLARIS THERAPEUTICS INC - HIGHLY STATISTICALLY SIGNIFICANT RESULTS AT PRIMARY ENDPOINT.  Full Article

Aclaris Therapeutics Qtrly Loss Per Share $1.21
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS, PROVIDES BUSINESS STRATEGY UPDATE AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.AS OF JUNE 30, 2019, CO HAD AGGREGATE CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $115.5 MILLION VERSUS $168.0 MILLION AS OF DEC 31, 2018.QTRLY NET REVENUES INCREASED TO $5.9 MILLION VERSUS $3.7 MILLION.QTRLY LOSS PER SHARE $1.21.REITERATES THAT IT EXPECTS 2019 GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $61 TO $64 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.76, REVENUE VIEW $5.5 MILLION -- REFINITIV IBES DATA.  Full Article

Aclaris Announces Positive 6-Month Results From Phase 2 Open-Label Clinical Trial Of ATI-502
Monday, 17 Jun 2019 

June 17 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS ANNOUNCES POSITIVE 6-MONTH RESULTS FROM A PHASE 2 OPEN-LABEL CLINICAL TRIAL OF ATI-502 TOPICAL IN PATIENTS WITH ANDROGENETIC ALOPECIA (MALE/FEMALE PATTERN-BALDNESS).ACLARIS THERAPEUTICS INC - 12-MONTH RESULTS FROM THIS TRIAL ARE EXPECTED BY YEAR END 2019..ACLARIS THERAPEUTICS INC - THROUGH RECENT FORMULATION WORK, CAN ACHIEVE SIGNIFICANTLY HIGHER TOPICAL CONCENTRATIONS OF ATI-502.ACLARIS - BELIEVES NEXT STEP IS INITIATING PHASE 2 DOSE-RANGING CLINICAL TRIAL WITH HIGHER CONCENTRATIONS OF ATI-502, WITH POTENTIALLY A FEMALE FOCUS.  Full Article

Aclaris Therapeutics Says Stephen Tullman Resigned As Chairman
Friday, 7 Jun 2019 

June 7 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS INC - STEPHEN TULLMAN RESIGNED AS CHAIRMAN.ACLARIS THERAPEUTICS INC SAYS STEPHEN TULLMAN RESIGNED AS CHAIRMAN AND AS A DIRECTOR OF BOARD EFFECTIVE JUNE 7 - SEC FILING.  Full Article

Aclaris Therapeutics Reports Qtrly Loss Per Share $0.91
Thursday, 9 May 2019 

May 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS.Q1 REVENUE $5.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $4.8 MILLION.QTRLY LOSS PER SHARE $0.91.  Full Article

Aclaris Therapeutics Announces Availability Of Eskata In The U.S.
Monday, 7 May 2018 

May 7 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS ANNOUNCES AVAILABILITY OF ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W).ACLARIS THERAPEUTICS INC - ESKATA IS NOW AVAILABLE FOR PURCHASE BY DERMATOLOGISTS IN THE UNITED STATES.  Full Article

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​.ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​.  Full Article

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.  Full Article

Aclaris Therapeutics says qtrly loss per share $0.63
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aclaris Therapeutics Inc -:Aclaris Therapeutics reports third quarter 2017 financial results.Aclaris Therapeutics Inc - qtrly loss per share $0.63.Aclaris Therapeutics Inc - qtrly revenue of $684,000.Aclaris Therapeutics Inc- ‍cash burn for 2017 is now estimated to be in range of $56 million to $59 million​.Aclaris Therapeutics Inc- ‍research and development expenses for 2017 are now estimated to be in range of $39 million to $42 million​.  Full Article